CTOs on the Move

Kansas Bioscience Organization

www.kansasbio.org

 
Kansas Bioscience Organization is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kansasbio.org
  • 8527 Bluejacket St
    Overland Park, KS USA 66214
  • Phone: 913.495.4334

Executives

Name Title Contact Details

Similar Companies

Travere Therapeutics

At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife

ASDI

ASDI is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Doctor's Best

We firmly believe in the integration of science research and traditional wisdom as the way that nutritional and herbal supplements will reach their exciting potential.   Founded in 1990 by a pioneering physician committed to science-based alternative health care, Doctor’s Best offers only the most important nutritional supplements. Careful research and precise formula development keeps us at the leading edge of quality, effectiveness, and innovation.   Containing the finest quality raw materials from around the world, Doctor’s Best supplements embody the best that traditional knowledge and current scientific research have to offer in the field of therapeutic nutrition. Countless hours have been spent analyzing scientific literature to provide sound alternatives to the proliferation of questionable supplements in the marketplace.   Each of our products is accompanied by an annotated ""Fact Sheet"" with detailed background information, structure-function statements, and scientific references that substantiate these statements. All structure-function statements have been filed with FDA in accordance with DSHEA regulations.

Greenstone Biosciences

Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.

Lyell

We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.